Early termination and nonpublication of phase III/IV melanoma clinical trials: a cross-sectional study
Our study confirms that early termination of phase III and IV melanoma trials doesn't raise a significant concern; however, diversified funding and broader geographic representation are needed to create more equitable and inclusive trials. We also suggest conducting further cross-sectional studies on phase I/II melanoma trials.
Authors
- Omar Jaber (ORCID: https://orcid.org/0000-0002-7207-8806)
- Rania A. Masri (ORCID: https://orcid.org/0000-0002-2937-6947)
- Yacob Saleh (ORCID: https://orcid.org/0000-0001-6698-0919)
- Shady N. Hayek (ORCID: https://orcid.org/0009-0009-7409-8075)
- Sameer Yaser (ORCID: https://orcid.org/0009-0004-6874-3393)
- Abdulrahman Nasir Al Khatib
Institutions
- University of Jordan (JO)
- MedStar Washington Hospital Center (US)
- Sparrow Health System (US)
- University of Michigan (US)
- King Hussein Cancer Center (JO)
- Sparrow Hospital (US)
- Washington Hospital (US)
Publication Details
- Journal
- Baylor University Medical Center Proceedings
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/08998280.2024.2439771
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00